|
|
|
|
Consultant's fears for hospital
A SENIOR general consultant surgeon, with more than twenty years experience, has spoken of his 'sadness' at the demise of services at Ipswich Hospital.When Alan Cameron first joined the hospital in 1988 he was so proud of the work being...
|
|
|
Oncolytics Completes Patient Enrollment For Cancer Trial
The study demonstrated a clinical benefit rate of 75% Oncolytics has completed the patient enrolment in the phase II component of a phase I/II UK trial of Reolysin combined with paclitaxel/carboplatin.It is intended for patients with...
|
|
|
Wilmington audiologist warns against hearing loss for cancer patients
While cancer patients and their families are aware of the many side effects that come with treatment like chemotherapy and radiation, they may not know that hearing loss is a real risk as well.Patients should speak with their...
|
|
|
Link Between Common Antibacterial Treatment And Sensorineural Hearing Loss In Cystic Fibrosis Patients
Between Common Antibacterial Treatment And Sensorineural Hearing Loss In Patients Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites details of 26,000 UK specialists medical software Ask a Doctor and Disease...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients...
|
|
|
Oncolytics Biotech completes enrollment in head and neck cancer trial
(Datamonitor via COMTEX) -- ONCY | Quote | Chart | News | PowerRating -- Oncolytics Biotech, a Canadian biopharmaceutical company, has completed patient enrollment in the Phase II component of a Phase I/II UK trial of Reolysin combined with...
|
|
|
Osaka City Uni Hospital Treats First Prostate Cancer Patients
(AsiaPulse via COMTEX) -- MEDIA RELEASE PR35234 (Full text of statement.Contact details below.) Osaka City University Hospital Treats First Prostate Cancer Patients With Elekta VMAT OSAKA, July 3 /PRNewswire-AsiaNet/ -- Osaka City...
|
|
|
Link Between Common Antibacterial Treatment And Sensorineural Hearing Loss In Cystic Fibrosis Patients
An otherwise effective treatment for cystic fibrosis places patients at a high risk of sensorineural hearing loss, according to new research published in the July edition of Otolaryngology-Head and Neck Surgery.Cystic fibrosis...
|
|
|
What Is Tinnitus? What Causes Tinnitus?
Tinnitus (from the Latin tinnitus or 'ringing') is a condition characterized by ringing, swishing, or other noises that appear to be originating in the ear or head.Not normally a dangerous or serious problem, tinnitus is usually a...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R)
Oncolytics Biotech(R) Inc.Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC,...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K.trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers. The principal investigators for the...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.(TSX:ONC,ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K
Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced ...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /CNW/ - Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
Companies: CALGARY, July 2 /CNW/ - Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel...
|
|
|
Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Combination Reolysin and Paclitaxel/Carboplatin He
CALGARY, July 2 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
Biotech(R) Inc.Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial s_account build_site_sections s.hier1 Members: Not ed? for free extra services?
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
(Canada NewsWire via COMTEX) -- ONCY | Quote | Chart | News | PowerRating -- Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY | Quote | Chart | News | PowerRating) announced today that patient enrolment has been completed in the Phase II...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /CNW/ - Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with...
|
|
|
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carbopla
CALGARY, July 2 /CNW/ - Oncolytics Biotech Inc.(TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for...
|
